Immune cells may lead to more Parkinson's cases in men
Peer-Reviewed Publication
Updates every hour. Last Updated: 10-May-2025 22:09 ET (11-May-2025 02:09 GMT/UTC)
Lowering the body temperature of preterm infants (born at 33 to 35 weeks of pregnancy) with hypoxic ischemic encephalopathy (HIE)—a type of brain damage caused by oxygen loss—offers no benefits over standard care, according to a study funded by the National Institutes of Health (NIH). Previous studies of near-term and term infants (born after 36 weeks) with HIE found that this cooling treatment, which lowers body temperature to about 92 degrees Fahrenheit, significantly reduced the risk of death or disability by age 18 months (corrected for prematurity). However, the current findings show that such benefits are not observed for preterm infants with HIE. The authors noted that use of the cooling treatment in preterm infants has increased, despite little research on its effectiveness in this age group.
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published today in Nature Cancer, the new approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.